{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:27:07Z","timestamp":1787027227121,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>A patient with schizophrenia who was treated with chlorpromazine developed lupus anticoagulant (LA) and antiphospholipid syndrome (APS). On protein electrophoresis, a monoclonal immunoglobulin A peak was seen in this patient, defining a condition of monoclonal gammopathy of undetermined significance. Additionally, \u03b2-thalassemia was diagnosed with the CD41-42 genotype. This condition is extremely rare, particularly in patients with schizophrenia and APS. We present a case of a patient with schizophrenia and secondary APS who had a positive LA, a significantly prolonged activated partial thromboplastin time, endogenous coagulation factor deficiency and inhibitor, no bleeding, and an unexpected finding of \u03b2-thalassemia and monoclonal IgA. Following that, a literature review on the disorders was presented.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1178247","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T01:34:38Z","timestamp":1680744878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A rare case of schizophrenia coexistence with antiphospholipid syndrome, \u03b2-thalassemia, and monoclonal gammopathy of undetermined significance"],"prefix":"10.3389","volume":"14","author":[{"given":"Yingming","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiquan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016.","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia.","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia.","volume":"381","author":"Marder","year":"2019","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-673601730-X","article-title":"Schizophrenia.","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jamapsychiatry.2014.1582","article-title":"Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.","volume":"71","author":"Konopaske","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"B6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci.","volume":"511","year":"2014","journal-title":"Nature."},{"key":"B7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","article-title":"Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.","volume":"50","author":"Pardi\u00f1as","year":"2018","journal-title":"Nat Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","article-title":"Rare coding variants in ten genes xonfer substantial risk for schizophrenia.","volume":"604","author":"Singh","year":"2022","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/157339510791823673","article-title":"Immune system and schizophrenia.","volume":"6","author":"M\u00fcller","year":"2010","journal-title":"Curr Immunol Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","article-title":"Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study.","volume":"168","author":"Benros","year":"2011","journal-title":"Am J Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.biopsych.2013.09.023","article-title":"The epidemiologic evidence linking autoimmune diseases and psychosis.","volume":"75","author":"Benros","year":"2014","journal-title":"Biol Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.biopsych.2018.06.016","article-title":"Associations between non-neurological autoimmune disorders and psychosis: a meta-analysis.","volume":"85","author":"Cullen","year":"2019","journal-title":"Biol Psychiatry."},{"key":"B13","year":"2014","journal-title":"Psychosis and schizophrenia in adults: treatment and management."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-022-00430-1","article-title":"Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic.","volume":"22","author":"Vita","year":"2023","journal-title":"Ann Gen Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1055\/a-1854-0185","article-title":"Pharmacological treatment of early-onset schizophrenia: a critical review, evidence-based clinical guidance and unmet needs.","volume":"55","author":"Lopez-Morinigo","year":"2022","journal-title":"Pharmacopsychiatry."},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpsy.2004.06.031","article-title":"Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.","volume":"19","author":"Lambert","year":"2004","journal-title":"Eur Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/0091217416636601","article-title":"Medication adherence in patients with schizophrenia.","volume":"51","author":"Phan","year":"2016","journal-title":"Int J Psychiatry Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome.","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3109\/07853899309147317","article-title":"Autoimmunity in schizophrenia: a review of recent findings.","volume":"25","author":"Ganguli","year":"1993","journal-title":"Ann Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1176\/ajp.153.12.1530","article-title":"Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia.","volume":"153","author":"Wright","year":"1996","journal-title":"Am J Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.psychres.2010.04.049","article-title":"Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia.","volume":"187","author":"Chang","year":"2011","journal-title":"Psychiatry Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.2830270408","article-title":"Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis.","volume":"27","author":"Canoso","year":"1988","journal-title":"Am J Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jpsychires.2008.09.009","article-title":"Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients.","volume":"43","author":"Shen","year":"2009","journal-title":"J Psychiatr Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s12026-017-8895-1","article-title":"Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature.","volume":"65","author":"Regina","year":"2017","journal-title":"Immunol Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-thalassemias.","volume":"384","author":"Taher","year":"2021","journal-title":"N Engl J Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.psychres.2007.11.001","article-title":"Schizophrenia and beta-thalassemia: a genetic link?","volume":"158","author":"Borras","year":"2008","journal-title":"Psychiatry Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/ejh.13563","article-title":"Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance.","volume":"106","author":"Baldursd\u00f3ttir","year":"2021","journal-title":"Eur J Haematol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876271","article-title":"Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance.","volume":"13","author":"Sigurbergsd\u00f3ttir","year":"2022","journal-title":"Front Immunol."},{"key":"B29","first-page":"690","article-title":"Chinese expert consensus on operation procedure and result interpretation of APTT mixing test.","volume":"44","year":"2021","journal-title":"Chin J Lab Med."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25669","article-title":"Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests.","volume":"95","author":"Favaloro","year":"2020","journal-title":"Am J Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.25836","article-title":"Alternative assays to dRVVT and aPTT for lupus anticoagulant detection.","volume":"95","author":"Moore","year":"2020","journal-title":"Am J Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/ijlh.12227","article-title":"Commonalities and contrasts in recent guidelines for lupus anticoagulant detection.","volume":"36","author":"Moore","year":"2014","journal-title":"Int J Lab Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/0961203314558859","article-title":"Lupus anticoagulant-hypoprothrombinemia syndrome: report of two cases and review of the literature.","volume":"24","author":"Mulliez","year":"2015","journal-title":"Lupus."},{"key":"B34","first-page":"450","article-title":"Causes of isolated prolonged activated partial thromboplastin time in an acute care general hospital.","volume":"46","author":"Chng","year":"2005","journal-title":"Singapore Med J."},{"key":"B35","first-page":"46","article-title":"Laboratory diagnosis of lupus anticoagulant associated by coagulation factors (FVIII, FIX and FXI) deficiency: report of 13 cases.","volume":"31","author":"Yang","year":"2008","journal-title":"Chin J Lab Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3969\/j.issn.1672-9455.2021.24.023","article-title":"Using dilution method to evaluate the interference of lupus anticoagulant in the detection of coagulation factor activity.","volume":"18","author":"Yan","year":"2021","journal-title":"Lab Med Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40263-013-0085-7","article-title":"Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.","volume":"27","author":"Kishi","year":"2013","journal-title":"CNS Drugs."},{"key":"B38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/0006-322390467-g","article-title":"Neuroleptic-associated autoantibodies. A prevalence study.","volume":"27","author":"Canoso","year":"1990","journal-title":"Biol Psychiatry."},{"key":"B39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ajh.2830020209","article-title":"A chlorpromazine-induced inhibitor of blood coagulation.","volume":"2","author":"Canoso","year":"1977","journal-title":"Am J Hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ajh.2830130204","article-title":"Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities.","volume":"13","author":"Canoso","year":"1982","journal-title":"Am J Hematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/ndt\/14.5.1335","article-title":"Inferior vena cava thrombosis in a patient with chlorpromazin-induced anticardiolipin antibodies.","volume":"14","author":"Ducloux","year":"1999","journal-title":"Nephrol Dial Trans."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.204","article-title":"Dysfunction in the coagulation system and schizophrenia.","volume":"6","author":"Hoirisch-Clapauch","year":"2016","journal-title":"Trans Psychiatry."},{"key":"B43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.17712\/nsj.2018.3.20180014","article-title":"Schizophrenia following new-onset refractory status epilepticus secondary to antiphospholipid syndrome.","volume":"24","author":"Al-Khateeb","year":"2019","journal-title":"Neurosciences."},{"key":"B44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.rdc.2017.06.004","article-title":"Central nervous system manifestations of antiphospholipid syndrome.","volume":"43","author":"Graf","year":"2017","journal-title":"Rheum Dis Clin North Am."},{"key":"B45","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bjh.12627","article-title":"Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics.","volume":"164","author":"Delluc","year":"2014","journal-title":"Br J Haematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3967\/bes2021.094","article-title":"Effectiveness of using mean corpuscular volume and mean corpuscular hemoglobin for beta-thalassemia carrier screening in the guangdong population of China.","volume":"34","author":"Gu","year":"2021","journal-title":"Biomed Environ Sci."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.894444","article-title":"Molecular spectrum, ethnic and geographical distribution of thalassemia in the southern area of hainan, China.","volume":"10","author":"Yu","year":"2022","journal-title":"Front Pediatr."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.874624","article-title":"Prevalence and genetic analysis of thalassemia and hemoglobinopathy in different ethnic groups and regions in hainan island, southeast China.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1534\/genetics.104.028217","article-title":"A genetic mechanism implicates chromosome 11 in schizophrenia and bipolar diseases.","volume":"167","author":"Klar","year":"2004","journal-title":"Genetics."},{"key":"B50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijdevneu.2017.06.007","article-title":"Hemoglobins emerging roles in mental disorders. Metabolical, genetical and immunological aspects.","volume":"61","author":"Altinoz","year":"2017","journal-title":"Int J Dev Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00439-006-0190-5","article-title":"Meta-analysis shows association between the tryptophan hydroxylase (TPH) gene and schizophrenia.","volume":"120","author":"Li","year":"2006","journal-title":"Hum Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/1076029615625825","article-title":"Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance.","volume":"22","author":"Crowley","year":"2016","journal-title":"Clin Appl Thromb Hemost."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1055\/a-1366-9379","article-title":"Antiphospholipid syndrome with monoclonal gammopathy-a mechanism for recurrent thrombosis?","volume":"121","author":"Doyle","year":"2021","journal-title":"Thromb Haemost."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood."},{"key":"B55","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid antibody syndrome.","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.16431","article-title":"What is the appropriate anticoagulation strategy for thrombotic antiphospholipid syndrome?","volume":"189","author":"Arachchillage","year":"2020","journal-title":"Br J Haematol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.mehy.2012.11.011","article-title":"Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance?","volume":"80","author":"Hoirisch-Clapauch","year":"2013","journal-title":"Med Hypotheses."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1178247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T01:34:47Z","timestamp":1680744887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1178247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2023.1178247"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1178247","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"article-number":"1178247"}}